Newsroom


Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.
19

Bausch + Lomb Acquires Doctor’s Allergy Formula Diagnostic System


System Delivers 3-Minute, Non-invasive Test to Identify Source of Patient’s Ocular Allergies

FOR RELEASE MONDAY, OCTOBER 19, 2015

BRIDGEWATER, NJ – Bausch + Lomb, a leading global eye healthy company, today announced that it has entered into a definitive agreement to acquire Doctor’s Allergy Formula, LLC, which will be integrated under the company’s pharmaceuticals division. 


The FDA-approved in-office Doctor’s Allergy Formula test enables eye care practitioners to objectively diagnose and identify the root cause of patient’s ocular allergies. The three-minute ocular allergy diagnostic test utilizes a panel of 60 allergens that are specific to each region of the country and provides results within 15 minutes.

"The addition of the Doctor’s Allergy Formula to Bausch + Lomb’s Pharmaceuticals business will further enhance our diagnostic portfolio of products for eye care practitioners in the rapidly evolving segment of ocular surface disease," Tracy Valorie, senior vice president and general manager, Bausch + Lomb Pharmaceuticals. "We are committed to delivering meaningful products to serve the needs of the eye care community and their patients and Doctor’s Allergy Formula is just one example. We congratulate the Doctor’s Allergy Formula team for identifying and successfully addressing this important area of unmet need and look forward to working with them to bring the benefits of this innovative diagnostic test to even more of our customers." 

The knowledge obtained from the Doctor’s Allergy Formula test results can help physicians identify the offending allergens and aid physicians in developing a customized treatment protocol. The Doctor’s Allergy Formula test, which is typically covered by major medical insurances, helps to distinguish ocular surface disease pathology such as dry eyes, ocular allergies and blepharitis as routinely these signs and symptoms of OSD can be similar.

“Doctor’s Allergy Formula launched a little more than two years ago and has grown to be a leader in the diagnostic allergy market,” said Howard Loff, M.D., chief medical officer and founder of Doctor’s Allergy Formula, LLC. “With many  leading eye doctors utilizing the diagnostic system today, we are excited to be joining Bausch + Lomb to bring the benefits of this innovative test to even more ophthalmologists, which I believe will soon become the standard-of-care.”  

For more information on Doctor’s Allergy Formula, visit www.drsallergyformula.com.

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing, and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry, which are available in more than 100 countries. 

About Doctor’s Allergy Formula
Founded by ophthalmologists, Doctor's Allergy Formula, LLC. provides a Food and Drug Administration approved proprietary diagnostic test designed to objectively diagnose allergies. With a simple, no-needle, non-invasive test, eye care practitioners and their staff can objectively diagnose the source of ocular allergies to help determine the most appropriate treatment for patients in office. Based in Norcross, GA, the company was founded in 2013 by Howard J. Loff, MD, a board-certified ophthalmologist and fellowship trained in oculoplastic and reconstructive surgery.  For more information about Doctor’s Allergy Formula, visit www.drsallergyformula.com

 © 2015 Bausch & Lomb Incorporated.

News Media Contact
Kristy Marks
Manager, Product PR, Bausch + Lomb 
(585) 338-8095 or kristy.marks@bausch.com 


Actions: E-mail | Permalink |